QTRX Quote, Financials, Valuation and Earnings

Bruker has a net margin of -67.73% compared to Quanterix's net margin of 2.17%. Quanterix's return on equity of -14.39% beat Bruker's return on equity of 4.53%.

Quanterix has a consensus price target of $11.25, signalling upside risk potential of 98.76%. On the other hand Bruker has an analysts' consensus of $54.11 which suggests that it could grow by 30.26%. Given that Quanterix has higher upside potential than Bruker, analysts believe Quanterix is more attractive than Bruker.

Quanterix has a beta of 1.127, which suggesting that the stock is 12.667% more volatile than S&P 500. In comparison Bruker has a beta of 1.181, suggesting its more volatile than the S&P 500 by 18.13%.

Quanterix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bruker offers a yield of 0.47% to investors and pays a quarterly dividend of $0.05 per share. Quanterix pays -- of its earnings as a dividend. Bruker pays out 26.7% of its earnings as a dividend. Bruker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Quanterix quarterly revenues are $30.3M, which are smaller than Bruker quarterly revenues of $801.4M. Quanterix's net income of -$20.5M is lower than Bruker's net income of $17.4M. Notably, Quanterix's price-to-earnings ratio is -- while Bruker's PE ratio is 81.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quanterix is 1.63x versus 1.85x for Bruker. Usually stocks with elevated PS ratios are considered overvalued.

Hologic has a net margin of -67.73% compared to Quanterix's net margin of -1.73%. Quanterix's return on equity of -14.39% beat Hologic's return on equity of 11.45%.

Quanterix has a consensus price target of $11.25, signalling upside risk potential of 98.76%. On the other hand Hologic has an analysts' consensus of $69.34 which suggests that it could grow by 8.58%. Given that Quanterix has higher upside potential than Hologic, analysts believe Quanterix is more attractive than Hologic.

Quanterix has a beta of 1.127, which suggesting that the stock is 12.667% more volatile than S&P 500. In comparison Hologic has a beta of 0.553, suggesting its less volatile than the S&P 500 by 44.736%.

Quanterix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hologic offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Quanterix pays -- of its earnings as a dividend. Hologic pays out -- of its earnings as a dividend.

Quanterix quarterly revenues are $30.3M, which are smaller than Hologic quarterly revenues of $1B. Quanterix's net income of -$20.5M is lower than Hologic's net income of -$17.4M. Notably, Quanterix's price-to-earnings ratio is -- while Hologic's PE ratio is 26.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quanterix is 1.63x versus 3.69x for Hologic. Usually stocks with elevated PS ratios are considered overvalued.

Nuwellis has a net margin of -67.73% compared to Quanterix's net margin of -158.3%. Quanterix's return on equity of -14.39% beat Nuwellis's return on equity of -670.55%.

Quanterix has a consensus price target of $11.25, signalling upside risk potential of 98.76%. On the other hand Nuwellis has an analysts' consensus of $13.00 which suggests that it could grow by 2796.56%. Given that Nuwellis has higher upside potential than Quanterix, analysts believe Nuwellis is more attractive than Quanterix.

Quanterix has a beta of 1.127, which suggesting that the stock is 12.667% more volatile than S&P 500. In comparison Nuwellis has a beta of 0.281, suggesting its less volatile than the S&P 500 by 71.882%.

Quanterix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nuwellis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Quanterix pays -- of its earnings as a dividend. Nuwellis pays out -- of its earnings as a dividend.

Quanterix quarterly revenues are $30.3M, which are larger than Nuwellis quarterly revenues of $1.9M. Quanterix's net income of -$20.5M is lower than Nuwellis's net income of -$3M. Notably, Quanterix's price-to-earnings ratio is -- while Nuwellis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quanterix is 1.63x versus 2.05x for Nuwellis. Usually stocks with elevated PS ratios are considered overvalued.

Varex Imaging has a net margin of -67.73% compared to Quanterix's net margin of 3.24%. Quanterix's return on equity of -14.39% beat Varex Imaging's return on equity of -7.36%.

Quanterix has a consensus price target of $11.25, signalling upside risk potential of 98.76%. On the other hand Varex Imaging has an analysts' consensus of $16.60 which suggests that it could grow by 112.82%. Given that Varex Imaging has higher upside potential than Quanterix, analysts believe Varex Imaging is more attractive than Quanterix.

Quanterix has a beta of 1.127, which suggesting that the stock is 12.667% more volatile than S&P 500. In comparison Varex Imaging has a beta of 0.697, suggesting its less volatile than the S&P 500 by 30.263%.

Quanterix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Varex Imaging offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Quanterix pays -- of its earnings as a dividend. Varex Imaging pays out -- of its earnings as a dividend.

Quanterix quarterly revenues are $30.3M, which are smaller than Varex Imaging quarterly revenues of $212.9M. Quanterix's net income of -$20.5M is lower than Varex Imaging's net income of $6.9M. Notably, Quanterix's price-to-earnings ratio is -- while Varex Imaging's PE ratio is 17.58x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quanterix is 1.63x versus 0.41x for Varex Imaging. Usually stocks with elevated PS ratios are considered overvalued.